Grace Therapeutics (GRCE) Common Equity (2017 - 2026)

Grace Therapeutics has disclosed Common Equity across 10 years of filings, most recently posting $48.2 million for Q2 2026.

• In Q2 2026, Common Equity fell 24.14% year-over-year to $48.2 million; the TTM figure through Jun 2026 stood at $48.2 million (down 24.14% YoY), while the FY2026 annual figure was $63.9 million, down 4.07% from the prior year.
• Common Equity came in at $48.2 million for Q2 2026 at Grace Therapeutics, down from $63.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $108.3 million in Q1 2022 to a low of $48.2 million in Q2 2026.
• Average Common Equity over 5 years is $70.7 million, with a median of $64.3 million recorded in 2023.
• Year-over-year, Common Equity soared 95.3% in 2022 and plunged 38.69% in 2023.
• Over 5 years, Common Equity stood at $96.7 million in 2022, then plunged by 33.13% to $64.7 million in 2023, then decreased by 19.39% to $52.1 million in 2024, then increased by 24.46% to $64.9 million in 2025, then dropped by 25.71% to $48.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $48.2 million in Q2 2026, $63.9 million in Q1 2026, and $64.9 million in Q4 2025.